22 This corresponded to a clinically meaningful 4.1-month prolongation in median progression-free survival from 2.8 months to 6.9 months.
In the present study, a 6.2-month prolongation in the median PFS was observed in patients who had undergone additional EUAS.
Despite diverse strategies for the treatment of patients with extensive SCLC, the results of phase III trials over the past 25 years have shown only a 2-month prolongation in median survival time between patients treated with different regimens (Chute et al, 1999).
22 At a median follow-up of 12.5 months, a 56% reduction in risk of progression was identified (HR 0.44; 95% CI 0.36 0.53; P<0.0001, local assessment), corresponding to a 4.2-month prolongation in median progression-free survival from 3.2 months to 7.4 months (Table 1).
The combination of CPT-11 with 5FU LV has not only led to a 15% increase in the response rate and a 3-month prolongation in the median progression-free time with respect to traditional 5FU LV regimens, but has also resulted in a 2 3-month increase of median survival (Douillard et al, 2 3-monthtz et al, 2000).
Median OS was almost identical at 19.5 months in the PLD arm but is now improved to 22.4 months in the trabectedin/PLD arm, i.e. a nearly 3-month prolongation in median survival for patients randomly assigned to the combination arm.
Concurrent TMZ with RT followed by adjuvant TMZ results in a 2.5-month prolongation of median survival among nGBM patients compared with patients receiving RT alone.
Despite a two-month prolongation, and due to the difficulties encountered in trying to recruit patients, the planned number of patients was not reach and the final analysis was based on only 248 files.
As shown in Figure 2A, a log-rank test using the Kaplan Meier method showed significant TTP prolongation in the low p-c-Jun expression group, compared with the high expression group (P=0.0028).
The memos emphasized a potential risk called QT prolongation, in which the heart delays recharging electrically.
